Sign in
NRXPW Stock Price, Chart, Stats & News
NRx Pharmaceuticals, Inc.
Save
NRx Pharmaceuticals, Inc. (NRXPW) does not currently pay a dividend.
361,784
Market cap
–
Current P/E
–
Forward P/E
NRXPW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.61% |
Operating margin | -1322.04% |
Pretax margin | -2336.57% |
Net margin | -2336.57% |
Effective tax rate | – |
ROA | -220.92% |
ROE | 111.73% |
D/E | -0.04x |
Interest coverage ratio | -24.14x |
NRXPW valuation
P/E | – |
P/S | 30.90x |
P/B | -4.36x |
P/CF | -4.92x |
P/FCF | -2.68x |
P/OCF | -4.92x |
PEG | -0.07x |
EV multiple | -1.35x |
About
NRx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development of novel therapies for central nervous system ailments and life-threatening lung conditions. Its portfolio includes ZYESAMI, an investigational medicine that has progressed through Phase IIb/III clinical trials for severe respiratory distress linked to COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, orally administered treatments engineered to address bipolar depression in individuals exhibiting both acute and sub-acute suicidal ideation and actions.
Similar securities
Based on sector and market capitalization
Report issue